Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R. Frank MJ, et al. Among authors: candia af. Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28. Cancer Discov. 2018. PMID: 30154192 Free PMC article. Clinical Trial.
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. Ribas A, et al. Among authors: candia af. Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. Cancer Discov. 2018. PMID: 30154193 Free PMC article. Clinical Trial.
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. Garon EB, et al. Clin Cancer Res. 2021 Aug 15;27(16):4566-4573. doi: 10.1158/1078-0432.CCR-21-0263. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108179 Clinical Trial.
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.
Jackson S, Candia AF, Delaney S, Floettmann S, Wong C, Campbell JD, Kell S, Lum J, Hessel EM, Traquina P, McHale M, Robinson I, Bell J, Fuhr R, Keeling D, Coffman RL. Jackson S, et al. Among authors: candia af. Clin Pharmacol Ther. 2018 Aug;104(2):335-345. doi: 10.1002/cpt.938. Epub 2017 Dec 6. Clin Pharmacol Ther. 2018. PMID: 29134633 Clinical Trial.
Small-Molecule TLR8 Antagonists via Structure-Based Rational Design.
Hu Z, Tanji H, Jiang S, Zhang S, Koo K, Chan J, Sakaniwa K, Ohto U, Candia A, Shimizu T, Yin H. Hu Z, et al. Cell Chem Biol. 2018 Oct 18;25(10):1286-1291.e3. doi: 10.1016/j.chembiol.2018.07.004. Epub 2018 Aug 9. Cell Chem Biol. 2018. PMID: 30100350 Free PMC article.
Pleiotrophin induces formation of functional neovasculature in vivo.
Christman KL, Fang Q, Kim AJ, Sievers RE, Fok HH, Candia AF, Colley KJ, Herradon G, Ezquerra L, Deuel TF, Lee RJ. Christman KL, et al. Among authors: candia af. Biochem Biophys Res Commun. 2005 Jul 15;332(4):1146-52. doi: 10.1016/j.bbrc.2005.04.174. Biochem Biophys Res Commun. 2005. PMID: 15949466
17 results